July 31, 2019 Another immuno-oncology mechanism threatens to disappoint As J&J tears up a licensing deal with Alligator, CD40 agonism might join the likes of Ox40 and IDO as an immuno-oncology approach that has failed to deliver.
June 05, 2019 Asco 2019 event analyser – low-key meeting belies some huge stock moves Mirati Therapeutics nearly stole the show at Asco despite not actually presenting – a fact that illustrates how low on meaningful data this year's conference was.
